Biopharmaceutical company Cell Therapeutics Inc (CTIC) Tuesday announced that the US Food and Drug Administration's Division of Oncology Products has notified to the company that its October 2011 resubmitted New Drug Application is considered a complete, Class 2 response to the FDA's April 2010 complete response letter.
The company further noted that the FDA has set a Prescription Drug User Fee Act, or PDUFA, goal date of April 24, 2012 for a decision on the new drug application, or NDA.
The NDA seeks accelerated approval of pixantrone to treat relapsed or refractory aggressive non-Hodgkin's lymphoma in patients who failed two or more lines of prior therapy.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.